Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03085992
Other study ID # TRUST
Secondary ID 2011-003340-45
Status Completed
Phase Phase 2
First received June 8, 2016
Last updated March 12, 2018
Start date March 2012
Est. completion date March 12, 2018

Study information

Verified date March 2018
Source Azienda Ospedaliero, Universitaria Pisana
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study includes patients affected by advanced and resectable rectal adenocarcinoma. It provides an induction chemotherapy with FOLFOXIRI regimen plus Bevacizumab followed by Chemoradiotherapy plus Bevacizumab. Surgery with total mesorectal incision must be performed within 7-9 weeks after this last treatment. The protocol will be evaluate the disease free survival at two years. Translational analyses will be performed to show the presence of VEGF polymorphism, CD133 surface markers on colorectal CSCs.


Recruitment information / eligibility

Status Completed
Enrollment 49
Est. completion date March 12, 2018
Est. primary completion date July 2017
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria:

- Histologically proven diagnosis of rectal adenocarcinoma. Diagnosis obtained by a biopsy technique which leaves the major portion of the tumor intact.

- Locally advanced, resectable disease defined by the presence of at least one of the following features: tumour extending to within 1 mm of or beyond the mesorectal fascia (ie, circumferential radial margin threatened or involved); lower third (= 6 cm from the anal verge) cT3 tumours; tumour extending 5 mm or more into perirectal fat; T4 tumour (ie, invading surrounding structures or peritoneum); clinical stage III disease (T1-4, N1-2), with the definition of a clinically positive lymph node being any node = 1.0 cm;

- Distal border of the tumor must be located < 12 cm from the anal verge.

- No evidence of metastatic disease by CT scan of the chest and abdomen and total body PET-CT scan.

- Tumor must be amenable to curative resection (curative resection can include pelvic exenteration).

- No history of invasive rectal malignancy, regardless of disease-free interval.

- No other rectal cancers (i.e., sarcoma, lymphoma, carcinoid, squamous cell carcinoma, or cloacogenic carcinoma) or synchronous colon cancer.

- No clear indication of involvement of the pelvic side walls by imaging.

- Age between 18 and 75 years.

- ECOG Performance status < 2 if age < 70 years and = 0 if age 71-75 years.

- Life expectancy of at least 5 years (excluding diagnosis of cancer).

- Hematopoietic: absolute neutrophil count = 1,000/mm3; platelet count = 100,000/mm3; haemoglobin level = 10 g/dL.

- Hepatic: total bilirubin = 1.5 times upper limit of normal (ULN); alkaline phosphatase = 2 times ULN; AST = 2 times ULN. [Note: *If AST>ULN, serologic testing for Hepatitis B and C must be negative].

- Renal: creatinine clearance > 50 mL/min; no renal disease that would preclude study treatment or follow-up.

- Written informed consent to experimental treatment and pharmacogenomic analyses.

Exclusion Criteria:

- Previous treatment with oxaliplatin, irinotecan or bevacizumab. Previous 5-fluorouracil or capecitabine treatment is allowed.

- Previous pelvic radiation therapy.

- Hepatic disease that would preclude study treatment or follow-up; uncontrolled coagulopathy; history of viral hepatitis or other chronic liver disease.

- Cardiovascular disease that would preclude study treatment or follow-up; New York Heart Association class III or IV heart disease; active ischemic heart disease; myocardial infarction within the past 6 months; symptomatic arrhythmia; uncontrolled hypertension.

- Lack of upper gastrointestinal tract integrity or malabsorption syndrome; active inflammatory bowel disease (i.e., patients requiring current medical interventions or who are symptomatic).

- Pregnant or lactating women. Fertile patients must use effective contraception (i.e double-barrier contraceptive measures, oral contraception or avoidance of intercourse during the study and for 30 days after surgery).

- Patients with prior malignancies (with the exception of rectal cancer), including invasive colon cancer, are eligible provided they have been disease-free for = 5 years and are deemed by their physician to be at low risk for recurrence.

- Other malignancy within the past 5 years with the exception of effectively treated squamous cell or basal cell skin cancer, melanoma in situ, carcinoma in situ of the cervix, or carcinoma in situ of the colon or rectum.

- Known hypersensitivity to fluorouracil, oxaliplatin or irinotecan or to Chinese hamster ovary cell proteins.

- Clinically significant peripheral neuropathy (i.e., neurosensory or neuromotor toxicity = grade 2).

- Psychiatric or addictive disorders, or other conditions that, in the opinion of the investigator, would preclude study participation

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
FOLFOXIRI plus Bevacizumab
BEVACIZUMAB 5 mg/kg over 30 minutes, day 1 IRINOTECAN 165 mg/sqm IV over 1-h, day 1 OXALIPLATIN 85 mg/sqm IV over 2-h, day 1 L-LEUCOVORIN 200 mg/sqm IV over 2-h, day 1 5-FLUOROURACIL 3200 mg/sqm IV 48-h continuous infusion, starting on day 1 administered every two weeks for 6 cycles (3 months).
Other:
Chemoradiotherapy plus Bevacizumab
FLUOROURACIL 225 mg/sqm/day by protracted IV continuous infusion or -CAPECITABINE 825 mg/sqm/bid p.o. continuously without interruption for all the duration of radiation treatment; EXTERNAL-BEAM IRRADIATION 50.4 GY in 28 daily fractions over 5.5 weeks; BEVACIZUMAB 5 mg/kg over 30 minutes, starting on day 1 of radiation treatment day 1 and then every two weeks (for 3 cycles).

Locations

Country Name City State
Italy Irccs Istituto Oncologico Veneto Padova
Italy Polo Oncologico Area Vasta Nord Ovest Pisa
Italy ausl5 di Pisa Pontedera
Italy Dipartimento Oncologico AUSL 7 Siena

Sponsors (1)

Lead Sponsor Collaborator
Azienda Ospedaliero, Universitaria Pisana

Country where clinical trial is conducted

Italy, 

Outcome

Type Measure Description Time frame Safety issue
Primary Disease-free survival rate at 2 years Disease-free survival is defined as time from study entry until progression of disease (according to RECIST 1.1) or death from any cause. Patients who are alive without having progressed at the end of the study will be censored at their last radiological assessment. Up to 2 years
Secondary Response rate Response rate is defined as the fraction of treated patients who achieve a response as defined according to Response Evaluation Criteria in Solid Tumors (RECIST) criteria vers. 1.1. Up to 2 years
Secondary Toxicity Rate Toxicity Rate is defined as the percentage of patients, relative to the total of enrolled subjects, experiencing treatment-related adverse events as assessed by National Cancer Institute Common Toxicity Criteria (version 3.0), during induction and concomitant chemoradiotherapy Up to 2 years
Secondary Overall survival Overall survival is defined as the time from study entry until death from any cause. Patients who are alive at the end of the study will be censored at that point. Up to 2 years
Secondary Pathological complete response rate Pathological complete response rate is defined as the fraction of treated patients who achieve pathological response after treatment Up to 2 years
See also
  Status Clinical Trial Phase
Recruiting NCT06380101 - Evaluating a Nonessential Amino Acid Restriction (NEAAR) Medical Food With Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer (LARC) N/A
Active, not recruiting NCT05551052 - CRC Detection Reliable Assessment With Blood
Recruiting NCT04323722 - Impact of Bladder Depletion on Mesorectal Movements During Radiotherapy in Rectal Cancer N/A
Recruiting NCT06006390 - CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors Phase 1/Phase 2
Active, not recruiting NCT04088955 - A Digimed Oncology PharmacoTherapy Registry
Active, not recruiting NCT01347697 - Collagen Implant (Biological Mesh) Versus GM Flap for Reconstruction of Pelvic Floor After ELAPE in Rectal Cancer N/A
Recruiting NCT04495088 - Preoperative FOLFOX Versus Postoperative Risk-adapted Chemotherapy in Patients With Locally Advanced Rectal Cancer Phase 3
Withdrawn NCT03007771 - Magnetic Resonance-guided High-Intensity Focused Ultrasound (MR-HIFU) Used for Mild Hyperthermia Phase 1
Terminated NCT01347645 - Irinotecan Plus E7820 Versus FOLFIRI in Second-Line Therapy in Patients With Locally Advanced or Metastatic Colon or Rectal Cancer Phase 1/Phase 2
Not yet recruiting NCT03520088 - PROSPECTIVE CONTROLLED AND RANDOMIZED STUDY OF THE GENITOURINARY FUNCTION AFTER RECTAL CANCER SURGERY IN RELATION TO THE DISSECTION OF THE INFERIOR MESENTERIC VESSELS N/A
Recruiting NCT05556473 - F-Tryptophan PET/CT in Human Cancers Phase 1
Recruiting NCT04749381 - The Role of TCM on ERAS of Rectal Cancer Patients Phase 2
Enrolling by invitation NCT05028192 - Mitochondria Preservation by Exercise Training: a Targeted Therapy for Cancer and Chemotherapy-induced Cachexia
Recruiting NCT03283540 - Transanal Total Mesorectal Excision for Rectal Cancer on Anal Physiology + Fecal Incontinence
Completed NCT04534309 - Behavioral Weight Loss Program for Cancer Survivors in Maryland N/A
Recruiting NCT05914766 - An Informational and Supportive Care Intervention for Patients With Locally Advanced Rectal Cancer N/A
Recruiting NCT04852653 - A Prospective Feasibility Study Evaluating Extracellular Vesicles Obtained by Liquid Biopsy for Neoadjuvant Treatment Response Assessment in Rectal Cancer
Recruiting NCT03190941 - Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients Phase 1/Phase 2
Completed NCT02810652 - Perioperative Geriatrics Intervention for Older Cancer Patients Undergoing Surgical Resection N/A
Terminated NCT02933944 - Exploratory Study of TG02-treatment as Monotherapy or in Combination With Pembrolizumab to Assess Safety and Immune Activation in Patients With Locally Advanced Primary and Recurrent Oncogenic RAS Exon 2 Mutant Colorectal Cancer Phase 1